1. A DOUBLE‐BLIND, RANDOMIZED PHASE 3 STUDY TO COMPARE EFFICACY AND SAFETY OF CT‐P10 TO RITUXIMAB IN COMBINATION WITH CVP IN PATIENTS WITH ADVANCED‐STAGE FOLLICULAR LYMPHOMA. (June 2017) Authors: Buske, C.; Kim, W.; Kwak, L.; Coiffier, B.; Jurczak, W.; Sancho, J.M.; Zhavrid, E.; Kim, J.; Hernández Rivas, J.Á.; Prokharau, A.; Vasilica, M.; Nagarkar, R.; Osmanov, D.; Lee, S.; Lee, S.; Bae, Y.; Ogura, M. Journal: Hematological oncology Issue: Volume 35(2017)Supplement 2 Page Start: 218 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. A HEAD‐TO‐HEAD PHASE 3 STUDY COMPARING BGB‐3111 AND IBRUTINIB IN PATIENTS WITH WALDENSTRÖM MACROGLOBULINEMIA. (June 2017) Authors: Buske, C.; LeBlond, V.; Novotny, W.; Owen, R.; Tedeschi, A.; Atwal, S.; Cohen, A.; Huang, J.; Tam, C.S. Journal: Hematological oncology Issue: Volume 35(2017)Supplement 2 Page Start: 422 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. A PIVOTAL, RANDOMIZED, DOUBLE‐BLIND, PLACEBO‐CONTROLLED, TWO‐ARM, PHASE 2 STUDY OF ME‐401 INVESTIGATING TWO DOSING SCHEDULES IN PATIENTS WITH FOLLICULAR LYMPHOMA (FL) AFTER FAILURE OF TWO OR MORE PRIOR SYSTEMIC THERAPIES. (12th June 2019) Authors: Zelenetz, A.; Zinzani, P.; Buske, C.; Ribrag, V.; Cunningham, D.; Jurczak, W.; Abrisqueta, P.; Agajanian, R.; Chaudhry, A.; Kayyal, T.; Wood, J.; Llorin‐Sangalang, J.; Brown, J. Journal: Hematological oncology Issue: Volume 37(2019)Supplement 2 Page Start: 556 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Hairy cell leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†. (12th August 2015) Authors: Robak, T.; Matutes, E.; Catovsky, D.; Zinzani, P. L.; Buske, C. Journal: Annals of oncology Issue: Volume 26(2015)Supplement 5 Page Start: v100 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. IBRUTINIB FOR THE TREATMENT OF BING‐NEEL SYNDROME: A RETROSPECTIVE, MULTICENTER STUDY. (12th June 2019) Authors: Castillo, J.; Itchaki, G.; Paludo, J.; Varettoni, M.; Buske, C.; Eyre, T.; Chavez, J.; Shain, K.; Issa, S.; Palomba, L.; Pasvolsky, O.; Simpson, D.; Talaulikar, D.; Tam, C.; Tedeschi, A.; Ansell, S.; Nayak, L.; Treon, S. Journal: Hematological oncology Issue: Volume 37(2019)Supplement 2 Page Start: 183 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. P1161: ASPEN: LONG-TERM FOLLOW-UP RESULTS OF A PHASE 3 RANDOMIZED TRIAL OF ZANUBRUTINIB (ZANU) VS IBRUTINIB (IBR) IN PATIENTS (PTS) WITH WALDENSTRÖM MACROGLOBULINEMIA (WM). (23rd June 2022) Authors: Dimopoulos, M.; Opat, S.; D'Sa, S.; Jurczak, W.; Lee, H.-P.; Cull, G.; Owen, R. G.; Marlton, P.; Wahlin, B. E.; Garcia-Sanz, R.; McCarthy, H.; Mulligan, S.; Tedeschi, A.; Castillo, J. J.; Czyz, J.; Fernandez De Larrea Rodriguez, C.; Belada, D.; Libby, E.; Matous, J.; Motta, M. Journal: HemaSphere Issue: Volume 6(2022)Supplement 3 Page Start: 1048 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. PATIENT‐REPORTED OUTCOMES (PROs) IN WALDENSTRÖM MACROGLOBULINEMIA (WM) PATIENTS TREATED WITH IBRUTINIB‐RITUXIMAB IN THE INNOVATE STUDY. (12th June 2019) Authors: Tedeschi, A.; Dimopoulos, M.A.; Trotman, J.; García‐Sanz, R.; Macdonald, D.; Mahe, B.; Herbaux, C.; Heffner, L.T.; Tam, C.S.; Varettoni, M.; Palomba, M.L.; Matous, J.V.; Shustik, C.; Kastritis, E.; Treon, S.P.; Li, J.; Poulsen, E.G.; Hauns, B.; Buske, C.; Leblond, V. Journal: Hematological oncology Issue: Volume 37(2019)Supplement 2 Page Start: 235 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. PB2081: TREATMENT PERSISTENCE AND ADHERENCE TO IBRUTINIB IN PATIENTS WITH WALDENSTRÖM MACROGLOBULINEMIA: A GERMAN CLAIMS DATA ANALYSIS. (23rd June 2022) Authors: Buske, C.; Hess, G.; Bahar, N.; Yang, K.; Tang, B.; Imhof, A.; Vinz, K.; Herweijer, E.; Herold, M. Journal: HemaSphere Issue: Volume 6(2022)Supplement 3 Page Start: 1952 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. PRELIMINARY CLINICAL DATA FROM A PHASE 1B STUDY OF MAVORIXAFOR AND IBRUTINIB IN PATIENTS WITH WALDENSTRöM MACROGLOBULINEMIA WITH MYD88 AND CXCR4 MUTATIONS. (17th June 2021) Authors: Treon, S.; Buske, C.; Thomas, S.; Branagan, A.; Dimopoulos, M.; Castillo, J. J.; Garzon, F.; Tang, W.; Ronan, R.; Seyffert, S.; Garg, V.; Ali, S.; Taveras, A.; Badarau, A.; Zmajkovicova, K.; Maier, S.; Maierhofer, B.; Matous, J. Journal: Hematological oncology Issue: Volume 39(2021)Supplement 2 Page Start: n/a Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. S206: OBINUTUZUMAB PLUS CHEMOTHERAPY DEMONSTRATES LONG-TERM BENEFIT OVER RITUXIMAB PLUS CHEMOTHERAPY IN PATIENTS WITH PREVIOUSLY UNTREATED FOLLICULAR LYMPHOMA: FINAL ANALYSIS OF THE GALLIUM STUDY. (23rd June 2022) Authors: Townsend, W.; Hiddemann, W.; Buske, C.; Cartron, G.; Cunningham, D.; Dyer, M. J.; Gribben, J.; Phillips, E.; Dreyling, M.; Seymour, J. F.; Grigg, A.; Lin, T.-Y.; Hong, X.-N.; Kingbiel, D.; Nielsen, T. G.; Knapp, A.; Herold, M.; Marcus, R. Journal: HemaSphere Issue: Volume 6(2022)Supplement 3 Page Start: 107 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗